Achieving DSC Certifications With Certified Nurse Specialists

Article

Improving patient care may be possible for institutions achieving Disease-Specific Care certifications with certified nurse specialists at the helm.

According to a presentation at the Oncology Nursing Society’s 46th Annual Congress, improving care for patients with cancer and elevating the role of clinical nurse specialists may be achieved with a Disease-Specific Care (DSC) certification from The Joint Commission.

“Disease-specific care certification focuses [on providing] a framework for continuous, reliable care and gives proof your program meets standards and verifies improvement activity,” said Kathy Burns, MS, APRN-CNS, AGCNS-BC, of The Ohio State’s James Cancer Hospital, which is one of only 3 hospitals in the United States to receive DSC certification for acute leukemia. “Basically, your program is doing what you are saying it’s doing. [It] provides accountability, decreases undesirable variations in care, advances patient outcomes, endorses cultural excellence, [and] provides the community with confidence that the program is providing the quality of care that it is marketing and delivering objectives of the certification [that] are a lasting commitment to clinical excellence for all of us,” Burns said.

Burns is also 1 of more than 72,000 clinical nurse specialists nationwide – a role that she says is vital in the healthcare arena.

“We drive practice change in the organization. [We] advocate to improve patient outcomes and mentor evidence-based practice projects, which I have to say is one of my favorites. We are required to take a course on [evidence-based practices] and then we are required to maintain those competencies. We collaborate on complex patient care issues with multidisciplinary teams throughout the system [and] promote standards on patient care and safety,” she said.

Clinical nurse specialists can also help their institutions achieve a DSC certification by recommending and implementing strategies to improve care and meet disease-specific indicators like:

  • Defining strategies to improve quality
  • Developing policies, procedures, results of tracers, and mock surveys to improve safety
  • Ensuring compliance with clinical practice and evidenced-based care

“Certification programs must demonstrate a systematic approach to care delivery and analysis,” Burns said. “Being at the table, we can help define strategies to improve quality.”

Reference

Burns K, Brown S. Disease Line Clinical Nurse Specialist: The Journey to Obtaining Disease-Specific Care Certification from The Joint Commission. Presented at: The Oncology Nursing Society 46th Annual Congress. April 20, 22, 27, and 29, 2021. Virtual

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content